Status:
COMPLETED
A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
Lead Sponsor:
LEO Pharma
Collaborating Sponsors:
Bayer
Conditions:
Papulopustular Rosacea
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus twice daily in the treatment of patients with papulopustular rosacea.
Detailed Description
To test the efficacy and safety of once vs twice daily application of azelaic acid 15% gel on papulopustular rosacea
Eligibility Criteria
Inclusion
- \- Papulopustular facial rosacea; minimum of 10, maximum of 50 inflamed papules and/or pustules
Exclusion
- Mild or severe rosacea
- Rosacea with marked ocular manifestations
- Presence of dermatoses that could interfere with the rosacea diagnosis or evaluation of the study course
- Wash out period required for patients treated prior to study with topical retinoids, oral antibiotics, topical antibiotics, systemic and topical corticosteroids, topical imidazole, laser surgery for telangiectasia
- History of hypersensitivity to propylene glycol
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00417937
Start Date
January 1 2007
End Date
June 1 2007
Last Update
June 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intendis GmbH
Berlin, Germany